Mirion Technologies, Inc. — Q3 2022 Form 10-Q
Business context and reporting period. Mirion supplies radiation detection, measurement, monitoring products and services across Medical and Industrial markets. This unaudited quarterly report covers the three and nine months ended September 30, 2022. Comparisons with 2021 are limited: the 2022 Successor results reflect acquisition-method purchase accounting following the October 2021 business combination, while 2021 is presented as Predecessor.
Financial performance and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $160.9m | $144.3m | $499.9m | $490.5m |
| Gross profit / margin | $69.8m / 43.4% | $61.9m / 42.9% | $213.1m / 42.6% | $204.0m / 41.6% |
| Operating loss | $(27.6)m | $(8.9)m | $(135.9)m | $(13.1)m |
| Net loss | $(50.4)m | $(46.7)m | $(128.7)m | $(141.3)m |
| Net loss attributable to Mirion shareholders | $(47.1)m | $(46.7)m | $(123.4)m | $(141.3)m |
- Q3 revenue rose $16.6m, led by Medical; Industrial revenue was essentially flat. For the nine-month period, Medical revenue increased to $195.6m from $155.6m, while Industrial revenue decreased to $304.3m from $334.9m.
- Q3 adjusted EBITDA, a non-GAAP measure, was $30.8m versus $30.9m; nine-month adjusted EBITDA was $108.3m versus $120.8m. Nine-month GAAP results included a $55.2m goodwill impairment charge.
- Nine-month operating cash flow was $14.2m versus $44.8m. Capital spending was $22.7m, yielding reported free cash flow of $(8.5)m; adjusted free cash flow was $16.4m, both non-GAAP measures.
- Cash and cash equivalents were $58.4m at September 30, down from $84.0m at December 31, 2021. Current assets were $438.0m and current liabilities $221.3m.
- Third-party borrowings totaled $826.7m gross, including $823.8m under the term loan; balance-sheet debt net of financing costs was $808.0m. The term-loan rate was 5.63%, up from 3.25% at year-end 2021. The $90m revolver had no borrowings and approximately $81.7m available after letters of credit. The company reported covenant compliance.
- Backlog/remaining performance obligations were $726.4m, down from $747.5m at December 31, 2021. The company expects to recognize approximately 26% in the remainder of 2022, 39% in 2023, 17% in 2024 and 7% in 2025, with the balance thereafter.
Material changes, outlook and risks
- Russia-Ukraine effects: A customer terminated a Finland nuclear project contract tied to approximately $67m of Mirion backlog, about 80% of which had been expected to convert to revenue over five years. Mirion recorded a $55.2m non-cash goodwill impairment; $165.1m of RMS goodwill remained at quarter-end. Russian-related project backlog was $94.9m, and sanctions had delayed revenue recognition. The filing says customers had not requested repayment of advance payments but could do so.
- Foreign exchange and supply chain: Currency movements reduced reported sales by approximately 5.7% in Q3 and 4.3% for the first nine months. If September 30 rates persisted through year-end, management estimated full-year sales would be about 5% lower year over year from currency effects. Supply constraints and higher material and freight costs delayed revenue and pressured margins, partly offset by price increases.
- Profitability and unusual items: SG&A increased, including acquisition-related amortization, stock compensation and public-company costs. Q3 included a $12.0m non-cash warrant fair-value loss; the nine-month period included a $27.5m non-cash warrant fair-value gain. Purchase-accounting amortization and depreciation also affected reported results.
- Outlook and liquidity: No specific revenue or earnings guidance is provided. Management said operating cash generation, together with long-term debt arrangements, should provide adequate liquidity for the next 12 months. It cautioned that financing access depends on market and company conditions. The fourth-quarter annual goodwill impairment assessment was still pending; further macroeconomic deterioration could lead to additional impairment.
- Other risks and contingencies: Risks include variable-rate debt and rising interest expense, fixed-price contract cost overruns, backlog conversion and government funding, sanctions and export controls, inflation, customer project delays, cybersecurity, regulatory compliance, and acquisition integration. Ordinary-course legal matters were not expected by management to have a material effect, though outcomes cannot be predicted. The filing reports effective disclosure controls and no material quarterly change in internal control over financial reporting.
Key facts for investors to verify
- How much of the $94.9m Russian-related backlog remains deliverable, and whether further project delays, cancellations or advance-payment claims arise.
- Whether operating cash flow recovers and working capital, inventory and capital spending trends support debt service.
- The effect of higher floating interest rates on interest expense and liquidity, alongside the company’s progress on LIBOR transition.
- Whether the Q4 goodwill assessment results in additional impairment and how reported performance compares with adjusted measures.
- How much currency pressure and supply-chain cost inflation persist, and whether pricing offsets those pressures.